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Background: The type-II-cytokine IFN-γ is a pivotal player in innate immune responses but also assumes functions
in controlling tumor cell growth by orchestrating cellular responses against neoplastic cells. The role of IFN-γ in
melanoma is not fully understood: it is a well-known growth inhibitor of melanoma cells in vitro. On the other
hand, IFN-γ may also facilitate melanoma progression. While interferon-regulated genes encoding proteins have
been intensively studied since decades, the contribution of miRNAs to effects mediated by interferons is an
emerging area of research.
We recently described a distinct and dynamic regulation of a whole panel of microRNAs (miRNAs) after
IFN-γ-stimulation. The aim of this study was to analyze the transcriptional regulation of miR-29 family members
in detail, identify potential interesting target genes and thus further elucidate a potential signaling pathway
IFN-γ→ Jak→ P-STAT1 → miR-29 → miR-29 target genes and its implication for melanoma growth.
Results: Here we show that IFN-γ induces STAT1-dependently a profound up-regulation of the miR-29 primary
cluster pri-29a~b-1 in melanoma cell lines. Furthermore, expression levels of pri-29a~b-1 and mature miR-29a and
miR-29b were elevated while the pri-29b-2~c cluster was almost undetectable. We observed an inverse correlation
between miR-29a/b expression and the proliferation rate of various melanoma cell lines. This finding could be
corroborated in cells transfected with either miR-29 mimics or inhibitors. The IFN-γ-induced G1-arrest of melanoma
cells involves down-regulation of CDK6, which we proved to be a direct target of miR-29 in these cells. Compared
to nevi and normal skin, and metastatic melanoma samples, miR-29a and miR-29b levels were found strikingly
elevated in certain patient samples derived from primary melanoma.
Conclusions: Our findings reveal that the miR-29a/b1 cluster is to be included in the group of IFN- and
STAT-regulated genes. The up-regulated miR-29 family members may act as effectors of cytokine signalling in
melanoma and other cancer cells as well as in the immune system.
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In the past decade, small non-coding microRNAs
(miRNAs) have been identified as new and important
players in post-transcriptional gene regulation and ever
since, their expression patterns and cellular functions
have been investigated in cancer and other diseases [1,2].
MiRNA biogenesis can be differentially regulated [3], but
generally starts with the generation of a primary (pri-)
miRNA transcript (several thousand nucleotides long),
which is subsequently processed into a 70–80 nucleotide
precursor form (pre-miRNA), which, following nuclear
export, is then cleaved into the ~22 nucleotide mature
miRNA. One strand of the mature duplex is incorporated
in the RISC (RNA-induced silencing complex), where
it recognizes, binds to and represses mRNA target
sequences [1]. MiRNAs are involved in many fundamen-
tal cellular processes as they are estimated to control
>50% of all protein-coding genes in mammals [4].
Consequently, they have been implicated in the regula-
tion of processes that promote cancer growth or con-
versely, in processes that might prevent cancers from
developing. For instance, a cancer cell can emerge fol-
lowing the over-expression of so-called “oncomirs” (such
as the miR-17-92 family, miR-21, -155, etc.) which down-
regulate tumor-suppressors that control cell proliferation.
On the other hand, miRNAs that function as tumor-
suppressors by targeting cellular oncoproteins (such as
let-7 family members, miR-15a, -16, -29, etc.) are fre-
quently down-regulated in cancer tissues [5]. Therapeu-
tics opting to replace the diminished tumor-suppressor
miRNAs are currently being investigated and seem
promising, as miRNAs exhibit high stability as well as
high specificity for their target mRNAs [5,6].
A disease where patients are in urgent need of more
effective treatments is advanced melanoma, the most
aggressive form of skin cancer. Metastatic melanoma
exhibit a severe resistance to therapy leading to 5-year
survival rates of below 5% [7]. Around 50% of patients
exhibit V600E mutations in the cellular kinase BRAF
[8]. Recently, the BRAF-inhibitor ZelborafW has been
approved for treatment of late-stage malignant melanoma
patients with V600E mutations, increasing life expectancy
by several months [9,10]. Nevertheless, except excision at
early stages, no curative therapies exist. Routinely, ther-
apies against melanoma include IFN-α as an adjuvant
treatment. Interferons are cytokines and constitute a
major part of the innate immune response, but they are
also recognized for their anti-proliferative properties. We
and others have shown that the type-II-cytokine IFN-γ
mediates growth inhibition of cancer cells by activating
the transcription factor STAT1 [11,12]. After IFN-γ
stimulation, STAT1 forms homodimers, which bind to
GAS (IFN-γ-activated sequences) elements in the pro-
moter regions of target genes. Very recently, we havefound several miRNAs to be dynamically regulated fol-
lowing stimulation with IFN-γ [13]. One of the first con-
nections between cytokine-induced Jak/STAT signaling
and miRNAs has been established by Löffler et al., who
showed that IL-6 increased the expression of oncogenic
miR-21 via STAT3 activation in myeloma cells [14]. The
signaling cascades involving IL-6 or IFN-α/β/STAT3/
miR-21 and others have been confirmed in several types
of cancer and diseases [15-17].
In the current study, we have focused on the biochem-
ical analysis of individual miRNAs regulated by IFN-γ
which we have recently identified in a detailed-time
course microarray experiment [13], and further concen-
trated on the interesting miRNA family miR-29 with its
three mature members, miR-29a, -29b and -29c. It is
transcribed into two primary transcripts, pri-29a~b-1
and pri-29b-2~c, from chromosomes 7 and 1, respect-
ively. MiR-29 family members target the expression of
proteins such as methyltransferases, extracellular matrix
proteins and transcription factors [18-20], which are
potentially involved in triggering enhanced invasion,
migration or proliferation of cells. They are silenced or
down-regulated in many types of cancer and have con-
sequently been assigned tumor-suppressing properties,
although in some cases also oncogenic roles have been
reported [21,22]. Here, we demonstrate a specific and pro-
found IFN-γ-induced, STAT1-dependent up-regulation
of miR-29a and -29b in melanoma cells and importantly,
also increased expression in primary melanoma patient
samples (but not in metastatic tumors) whereas the
second cluster pri-29b-2~c was consistently undetectable.
Moreover, we provide evidence for the tumor-suppressing
properties of miR-29 family members: inhibition of melan-
oma cell proliferation could be mediated by miR-29a,
which down-regulated CDK6 (cyclin-dependent kinase 6),
an important player in cell cycle G1/S transition. Our
findings identify the pri-29a~b-1cluster as a novel IFN-γ-
regulated gene and open up new connections between
miRNAs, interferon signaling and malignant melanoma,
which could lead to novel concepts for potential treat-
ment options in the future.
Results
To investigate possible transcriptional regulations of
miRNAs by STAT transcription factors, several melanoma
cell lines were treated with IFN-γ for different time
intervals and were subsequently analyzed by miRNA
microarray as previously described [13]. The top 10
IFN-γ-induced miRNAs from a microarray experiment,
which showed highest differential expression compared
to untreated cells, and detailed time-course expression
profiles thereof are depicted in Figure 1A and Additional
file 1: Figure S1. For further analysis, we focused on
the miR-29 family, as its mature members miR-29a and
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Figure 1 Top 10 IFN-γ-up-regulated miRNAs. (A) Ten miRNAs with highest positive fold changes (as determined by previous microarray
experiments [13]) include miR-29 family members (left). Detailed time course profiles are shown in Additional file 1: Figure S1. The miR-29 family
is transcribed from the respective antisense strand from two genetic clusters of chromosomes 7 (pri-29a~b-1) and 1 (pri-29b-2~c) (right).
The three mature forms miR-29a/29b/29c share the same seed region (grey box). Differences between the mature sequences are underlined;
a nucleotide difference between miR-29a and miR-29c is shown in italics. (B) The presumed pri-29a~b-1 promoter region [22-24] contains five
GAS-elements G1-5 (TT(C/A)CNNNAA(A/G)) and two ISRE-elements I1-2 ((G/A)(G/A)AANNGAAA(C/G)) (GRCh37/hg19).
Schmitt et al. Cell Communication and Signaling 2012, 10:41 Page 3 of 14
http://www.biosignaling.com/content/10/1/41miR-29b showed the most robust regulations across all
tested melanoma cell lines and because of its interesting
properties regarding tumor biology. To identify the pres-
ence of potential IFN-response elements, we performed
in silico screening of the promoter region 5 kb upstream
of a putative transcription start of pri-29a~b-1 [22-24]
and found five GAS-elements (TT(C/A)CNNNAA(A/G))
and two ISRE (interferon stimulated response element)-
elements ((G/A)(G/A)AANNGAAA(C/G)) (Figure 1B).
For control purposes, we selected miR-100, which was
slightly down-regulated after IFN-γ stimulation and
miR-25, whose levels were not induced in the micro-
array experiments. Other regulated candidates included
several miRNA star sequences (“miR*” which here repre-
sents the miR strand, which arises from the 3’-arm of the
hairpin, while the 5’-arm would be the guide or parent
strand and is conventionally considered as “minor”
product) which are currently being further assessed in
our laboratory (Figure 1, Additional file 1: Figure S1).
The pri-29a~b-1 cluster and mature miR-29a/29b are
regulated by IFN-γ
For stimulation experiments with IFN-γ, melanoma cell
lines MeWo and A375, as well as stably transfected
A375 derivates were used. A375-STAT1(F) represent
STAT1-dominant negative cells harboring a phenylalaninereplacement of tyrosine residue 701 crucial for STAT1
phosphorylation and dimerization [12]. Thus, transcrip-
tion of STAT1 target genes is abolished despite IFN-γ
stimulation. The corresponding control cells A375-
STAT1(wt) express the STAT1 wild-type construct instead
[12]. To accurately assess the regulation of the miR-29
family by IFN-γ-induced STAT1, we performed time
course experiments (Figure 2). Stimulation of A375,
MeWo and A375-STAT1(wt) cell lines with 50 ng/ml of
IFN-γ induced a prominent STAT1 phosphorylation,
which decreased after 48h of IFN-γ treatment, whereas
the STAT1-dominant negative cells A375-STAT1(F) only
exhibited a delayed and weak P-STAT1 signal after IFN-γ
stimulation (Figure 2A, see also [25]). Functional activity
of the P-STAT1 transcription factor was confirmed by
up-regulation of the STAT1 target genes IRF-1 and
STAT1 itself, which showed induced expression after
3h and 8h, respectively.
Following stimulation, changes in miRNA expression
levels were assessed by qRT-PCR (Figure 2B). A375,
A375-STAT1(wt) and MeWo cell lines showed a strong
and significant up-regulation (>5 fold) of the pri-29a~b-1
cluster, starting 24h after IFN-γ stimulation, while ex-
pression of the pri-29b-2~c cluster was not altered
(Figure 2B, upper panel). Accordingly, miRNA precursors
pre-29a and pre-29b-1 were also augmented whereas
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Figure 2 Expression profiles of miR-29 clusters in melanoma cells. A375-STAT1(F), A375-STAT1(wt), A375 and MeWo melanoma cells were
stimulated with IFN-γ for different time points. (A) Western Blot analysis (representative blots of biological triplicates) confirms activation of
P-STAT1 and induction of STAT1 and IRF-1 after IFN-γ stimulation while dominant negative A375-STAT1(F) cells show minor effects. (B) Time course
study of miRNA-expression after IFNγ-stimulation. Graphs show relative expression (REL) from quantitative qRT-PCR data for the pri-29a~b-1 and
the pri-29b-2~c clusters, the precursors pre-29a/29b-1/29b-2/29c and mature miR-29a/29b/25/100. Fold expression was calculated relative to the
untreated control and SDs are shown for biological triplicates. Statistical significance was tested with one-way ANOVA, followed by a Dunnett
Post-Hoc test with * p<0.05, ** p<0.01 and *** p<0.001. (C) MiRNA and miRNA* expression profiles in A375 cells derived from a more detailed IFN-γ
time course miRNA microarray experiment including cells treated with JI1 (IFN-γ stimulation for 72h after pre-treatment with JI1, black and grey
dots). Depicted are log2-values of the mean of duplicate microarray experiments.
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(Figure 2B, middle panel). Subsequently, significant up-
regulation of both mature miR-29a and miR-29b fol-
lowing IFN-γ stimulation was confirmed (Figure 2B,
lower panel). The two control amplifications of miR-100
(slightly down-regulated) and miR-25, which remained
stable over time following IFN-γ stimulation confirmed
the initial microarray-based expression profiles (Figure 2B,
lower panel). Similar regulation patterns were also found
in Jurkat and MT4 T-cells and in HEK293T kidney cells
(for mature miR-29a, miR-29b, and miR-25, Additional
file 2: Figure S2). Except for minor expression changes of
the Pri/Pre-miR-29 species after 72h of IFN-γ treatment,
no up-regulation was detected in the A375-STAT1(F)
dominant negative control cells, clearly suggesting that
STAT1 activity is required for the IFN-γ-induced regula-
tion of miR-29 family members.
Figure 2C shows expression results of a detailed time
course microarray experiment using IFN-γ-stimulated
A375 cells. In parallel and as described before, cells had
been pre-treated with Jak inhibitor 1 (JI1), which specif-
ically inhibits Janus tyrosine kinases and subsequently
prevented miR-29 up-regulation after IFN-γ stimula-
tion [13].
Altogether, these data substantiate for the first time
a time-dependent up-regulation of the expression of
pri-29a~b-1 cluster as well as of the mature miRNAs
miR-29a and -29b in melanoma cells, which is trig-
gered by IFN-γ-induced STAT1 signaling.
The miR-29b-2~c cluster is undetectable in melanoma cell
lines, melanocytes and keratinocytes
As both miR-29 primary clusters as well as the mature
miR-29a/29b showed different basal expression levels in
stimulation experiments and are known to be differen-
tially expressed in several types of cancer [26,27], we
next analyzed the miR-29 basal expression profiles in a
panel of melanoma cell lines, primary human melano-
cytes (NHEM-M2) and HaCaT keratinocytes (Figure 3A
and B). Pri-29a~b-1 was strongly expressed whereas pri-
29b-2~c was almost undetectable in all cell lines ana-
lyzed (Figure 3A). This is in accordance with previous
studies reporting down-regulation of the pri-29b-2~ccluster in rhabdomyosarcoma [28] and B-cell lymphoma
[23]. Also, mature miR-29a consistently showed higher
basal expression levels than miR-29b in all cell lines
examined (Figure 3B).
MiR-29a/29b expression levels inversely correlate with
growth behavior of melanoma cell lines
The classification of miR-29 as tumor-suppressor miRNA
has been widely accepted and the possibility to use syn-
thetic miR-29 as therapeutic agent in treatments of can-
cer seems to become increasingly realistic. Properties
counteracting the development and spreading of cancer
cells that have been observed in vitro and in vivo after
miR-29 overexpression include reduced invasion and
proliferation and induction of apoptosis [29,30]. These
findings prompted us to analyze a potential correlation
of basal miR-29 expression levels with cell growth.
Proliferation of untreated melanoma cell lines was moni-
tored over time (Figure 3C) in order to correlate the
growth rate with miR-29a and pri-29a~b-1 basal expres-
sion levels obtained from cells harvested 96h after seed-
ing. Melanoma cell lines were grouped in miR-29a and
pri-29a~b-1 ‘low-expression’ (A375, MeWo, IGR39,
WM9) and ‘high expression’ cell lines (FM55P, FM55M1,
SK-Mel30, IGR37) (Figure 3A and B). Generally, cell lines
with lower miR-29a showed an increased proliferation
rate compared to lines with higher basal miR-29a levels
(Figure 3C). Furthermore, the inverse correlation be-
tween pri-29a~b-1/miR-29a expression and the prolifera-
tion rate of melanoma cell lines might suggest a potential
involvement of miR-29 in anti-proliferative effects on
melanoma cells. To follow up these findings, we applied
miR-29a/29b mimics to A375 cells, which exhibit a rela-
tively low miR-29a/29b basal expression and, vice versa,
we applied a miR-29a inhibitor to FM55P cells, which
have a high basal miR-29a/29b expression (Figure 3B).
Proliferation assays with mimics and inhibitors and
the corresponding amounts of scrambled controls, NC
(negative control)-mimic and NC-inhibitor, corroborated
that miR-29 indeed inhibited growth of melanoma cells:
transfection of miR-29a/29b mimics caused a remarkable
reduction of proliferation as compared to NC-mimic-
transfected A375 cells (Figure 3D). In turn, FM55P cells,
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Figure 3 Inverse correlation of miR-29a expression levels and melanoma proliferation. Comparison of basal expression levels of
(A) primary miRNA clusters pri-29a~b-1 (blue/red/black bars) and pri-29b-2~c (grey bars) and (B) mature miR-29a (blue/red/black bars) and
miR-29b (grey bars) in NHEM-M2, eight melanoma cell lines and HaCaT keratinocytes. Graphs show 2-Δct x102 with SD of biological
triplicates. (C) Mean growth curves of untreated melanoma cell lines over 4 days (biological quadruplicates). Melanoma cell lines with ‘low
expression’ of pri-29a~b-1 and miR-29a show faster proliferation whereas cells with a relatively ‘high expression’ proliferate slower. (D,E)
Proliferation assay of (black) mimic/inhibitor- and (grey) NC-mimic/NC-inhibitor-transfected cells over 72h in (D) A375 and (E) FM55P cells;
representative graphs of four independent experiments. Error bars depict SDs of technical triplicates. The inserted graphs (upper left corners)
show the mean confluence of 4 biological replicates at 0h and 72h time points of the proliferation assay. Depicted are ratios of confluence
of 29ab-mimic/NC-mimic treated cells (D) and 29a-inhibitor/NC-inhibitor treated cells (E). Error bars show SEM. Significance was assessed by a
two-tailed t-test with * p<0.05, ** p<0.01 and *** p<0.001.
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NC-inhibitor-transfected control cells (Figure 3E).
MiR-29a/29b down-regulate CDK6, but not PI3K
MiR-29 is predicted to regulate more than 1000 human
genes (TargetScanHuman 6.1). We have used a combin-
ation of several algorithms (TargetScanHuman 6.1,
Diana-microT v3.0, microRNA.org) to compile a list of
potentially interesting genes, which carry predicted
miR-29 target sites. After detailed expression analysis of
potential candidates in melanoma cells and initial screen-
ing for their response to miR-29 mimic and inhibitor
treatment (data not shown), we concentrated on the
PI3K regulatory subunit (gene: PI3KR1; protein: PI3K/
p85α) and CDK6, which play important roles in cell cycle
control, cellular signaling and thus, proliferation. Both
have already been confirmed as miR-29 targets in several
cancers [31-34].
To assess the effect of miR-29 on CDK6 and PI3K
expression in melanoma, mRNA and protein levels were
examined after miR-29 mimic or inhibitor treatments by
qRT-PCR and quantitative immunoblotting, respectively
(Figure 4A and B). Combined transfection of miR-29a/
29b reduced CDK6 mRNA and protein levels in A375
cells as compared to scrambled controls whereas PI3K
levels were not affected (Figure 4A). In agreement with
that, knockdown of miR-29a in FM55P cells resulted in a
slight up-regulation of CDK6 levels while PI3K levels
remained unchanged (Figure 4B). These data indicate
that miR-29 is involved in down-regulation of CDK6
protein while PI3K was not specifically targeted in mel-
anoma cells. CDK6 was also down-regulated in response
to miR-29 induction after IFN-γ stimulation in A375
cells and A375-STAT1(wt) but not in A375-STAT1(F)
cells, suggesting STAT1 dependency (Figure 4C). In con-
trast, PI3K levels were reduced in all three cell lines,
hinting at STAT1-independent effects. To further prove
regulation of CDK6 by miR-29, we performed luciferase
assays with reporter constructs containing part of the
CDK6 3’-UTR, its three single miR-29 binding sites as
predicted by TargetScan (www.targetscan.org), part of
the PI3KR1-3’-UTR or the miR-29a full complementary
sequence as a positive control (Figure 4D). Luciferase
activity, as compared to the respective negative control,
dropped by ~60 % for both time points in A375 melanoma
cells when the CDK6 3’-UTR construct was co-transfected
with miR-29a mimic. The corresponding single binding
sites contributed to this suppression significantly with
38% (BS1), 34% (BS2) and 35% (BS3) (Figure 4E). This
suggests that all three miR-29 binding sites partake in the
suppression of CDK6. Surprisingly, the PI3KR1 construct
was also significantly suppressed by the miR-29a mimic
in luciferase assays (Figure 4E) while only marginal
effects had been observed on mRNA and protein level(Figure 4A,B). Taken together, these findings indicate
that both CDK6 and PI3KR1 3’-UTRs are directly tar-
geted by miR-29 in melanoma cells; however, only CDK6
suppression seems to be important in a cellular context.
To further explore the relevance of reduced CDK6 levels
in the cell, we used siRNA against CDK6 and assessed
proliferation over 72h in A375 (Figure 4F) and FM55P
cells (Figure 4G). Reduction of CDK6 mRNA and protein
level (Additional file 3: Figure S3) led to a clearly dimin-
ished proliferation in both cell lines.MiR-29a and miR-29b are up-regulated in primary
melanoma patient samples
Finally, we investigated miR-29a/29b expression profiles
in FFPE melanoma patient samples from normal skin,
nevi, primary and metastatic melanoma by qRT-PCR
(Figure 5). Nevi represent the most appropriate control
samples as they contain predominantly melanocytes
while normal skin samples are mostly composed of kera-
tinocytes. In comparison to healthy skin and nevi, both
miR-29a and miR-29b showed an up-regulation in pri-
mary melanoma samples whereas in metastatic tumors,
expression levels were only slightly enhanced compared to
healthy controls. Closer sub-classification of the patient
samples revealed, however, that only two of five patients
demonstrated the enhanced miR-29a/29b expression, in-
dicating that expression levels are heterogeneous and will
have to be assessed in larger patient cohorts.Discussion
Generally, expression levels of miRNAs can be regulated
transcriptionally, by epigenetic silencing or different turn-
over times [1,35,36]. The role of cytokines as inducers of
miRNA expression has recently been proposed in several
studies and examples for cytokine-induced miRNA up-
or down-regulation include pro-inflammatory signaling
molecules like TNF-α and IL1-β [37,38]. Interferons are
central players in tumor-immune interactions [39,40]. In
this context, the theory of ‘cancer immunosurveillance’,
defined as the immunological protection of the host
against development of cancer, has evoked much interest
during the last decade: mediated by the host’s immune
system, it is triggered by immune recognition of stress
ligands or antigens expressed on transformed cells.
IFN-γ has long been recognized for its crucial role in
defense against viral and bacterial infections as well as
in tumor control [40,41]. It primarily signals through the
Jak/STAT pathway and activated STAT1 homodimers
bind to GAS-elements in promoter regions of target
genes, while IFN-α/β signal additionally through ISRE–
elements. In our study, we have identified several GAS-
elements in the proposed pri-29a~b-1 promoter region.
IFN-γ stimulation of a control cell line expressing
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Figure 4 Effects of miR-29 on target genes CDK6 and PI3K. (A,B) relative mRNA and protein expression levels (REL) of miR-29 target genes
CDK6 (dark grey) and PI3K (light grey), assessed 24h, 48h and 72h after mimic/inhibitor transfection compared to NC-mimic/NC-inhibitor
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cause an up-regulation of miR-29, providing strong evi-
dence that STAT1 is indeed mediating IFN-γ-induced
effects on miR-29 expression levels.
IFN-γ has anti-proliferative effects on cancer cells
including melanoma [11,12] and we show here that
miR-29a, which is induced by IFN-γ exhibited the
same effects. Overall effects on growth were relatively
small, but robust and reproducible, considering that we
only manipulated levels of one miRNA and only used
relatively small amounts of mimics/inhibitors (50 nM/
150 nM) to be as close as possible to physiological rele-
vance. However, IFN-γ may also facilitate melanoma pro-
gression: Zaidi et al. have shown that IFN-γ-producing
macrophages are recruited to the UV-exposed skin and
can stimulate proliferation and migration of melanocytes
as well as induce expression of genes implicated in
immunoevasion and survival. When added to trans-
planted melanoma, these skin-recruited macrophages
enhanced the growth and survival of melanoma. All these
effects were IFN-γ-dependent as demonstrated by anti-
body blocking of IFN-γ [42].In our study, analysis of primary and metastatic mel-
anoma patient samples revealed increased miR-29a/29b
expression in some primary tumor samples in compari-
son to normal skin, nevi and metastatic tissue while all
metastatic lesions had low levels of these miRNAs.
Possibly, IFN-γ, which can be produced by macro-
phages, T cells and NK cells induces miR-29 expres-
sion via STAT1. miR-29a/29b were only up-regulated
in two out of five primary melanoma patients. In this
respect, it is interesting to note that IFN-γ producing
macrophages have been observed in 70 % of melanoma
samples [42]. A further evaluation of a larger panel of
patient samples including early neoplasia and advanced
metastatic stages is needed where a special focus will
be placed on immune cell infiltration, interferon con-
centration and an interferon-responsive gene signature.
miR-29 has very recently been linked to interferon
biology: it directly targets IFN-γ [43,44], the transcrip-
tion factors Tbet and Eomes crucial for IFN-γ expression
[19,44], and the receptor IFNAR1 [45], thereby drastic-
ally affecting immune regulation such as T cell
polarization and thymic function.
While this manuscript was in preparation, IFN-γ in-
volvement in the regulation of miR-29 expression was
also reported by a group studying T cell activation and
polarization in autoimmune diseases [44]. We here con-
firmed IFN-γ-induced miR-29 up-regulation in T cells
(Jurkat and MT4, Additional file 2: Figure S2) and have
also observed this effect in human embryonic kidney
cells implying a regulatory mechanism of broader rele-
vance. Interestingly, also type I interferons led to an
up-regulation of miR-29 (Additional file 2: Figure S2).
Screening of a panel of melanoma cell lines for dif-
ferent miR-29 species and family members revealed
that the pri-29b-2~c cluster was almost not expressed
and that miR-29a exhibited a much higher basal ex-
pression level than miR-29b. In tumor cells, reduced
miR-29 expression is frequently observed and diminished
expression of miRNAs in general is often associated
with enhanced oncogenesis [5,46]. The difference in
pri-29a~b-1 and pri-29b-2~c expression levels, which we
w?>havedetected, is consistentwithother typesofcancer, in
which the pri-29b-2~c cluster was mostly down-regulated
[26-28]. The fact thatmiR-29 familymembers are often not
expressed in cancer cells could be crucial for cancer control:
miR-29 down-regulates important genes such as CDC42,
TCL-1 and MCL-1, which normally confer tumor-
suppressing traits. In this context, anti-proliferating as
well as anti-invasive and pro-apoptotic effects have
been observed after miR-29 re-introduction in a variety
of cancer cells [29,30]. In line with this, we show anti-
proliferative effects of miR-29 and confirm for the first
time CDK6 as a direct miR-29 target in melanoma cells.
This suggests that miR-29-mediated down-regulation of
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miR-29a/b-mimic-transfected melanoma cells. SiRNA-
mediated knockdown of CDK6 resulted in reduced
proliferation of melanoma cells similar to what has
been shown for other cancer types [47,48]. CDK6
plays a pivotal role in control of G1/S cell cycle tran-
sition [49] and loss thereof is a common event in
neoplastic growth [50]. Noteworthy, CDK6 has also
been shown to be a direct miR-29 target in mantle
cell lymphoma [31], acute myeloid leukemia [34] and
cervical cancer [32].
The numerous anti-proliferative effects of IFN-γ in
many cancers may in part be explained by a G1 arrest in-
volving down-regulation of G1/S cyclins (cyclins A and E)
and CDK2/4 [12]. Accordingly, we find that IFN-γ as well
as miR-29 exhibit anti-proliferative activities in melan-
oma cells involving down-regulation of cell cycle control
players such as CDK6. The relevance of CDK6 activity
for melanoma growth is further emphasized by the fact
that the tumor suppressor p16INK4A (an inhibitor for
CDK6 and 4) is deleted in about 50% of melanoma
patients [51,52]. Here, we describe for the first time that
CDK6 is a direct target of miR-29 involved in regulating
growth behavior of melanoma cells.Conclusion
Our study extends the current knowledge on the miRNA
family miR-29, adding a novel regulatory loop of IFN-γ-
mediated Jak/STAT signaling in melanoma cells. Figure 6
summarizes the proposed regulatory circuit involving
IFN-γ and miR29: IFN-γ, which is e.g. secreted by
macrophages following diverse assaults such as infections
or UV light induces a STAT1-dependent up-regulation of
miR-29, which in turn can down-regulate IFN-γ expres-
sion directly and indirectly via T-bet and Eomes. Down-
regulation of cell cycle regulators like CDK6 contributes
to IFN-γ-mediated growth arrest.
We report that the pri-29 b-2~c cluster is almost un-
detectable in melanoma, which might markedly reduce
the ability of the miR-29 family to exhibit its tumor-
suppressing properties in these cancer cells. The fact
that miR-29a and miR-29b had enhanced expression
levels in some primary melanoma patients but not in
metastatic tumor samples is in line with many studies
showing down-regulation or low levels of miR-29 in
various advanced cancers [21,22,31,53]. We hypothesize
that the reduced miR-29 expression in cancer cells could
be a consequence of diminished IFN-γ signaling in those
cells, which might already have escaped immune sur-
veillance [41]. In regard to the proposed regulatory cir-
cuit, our study may open new connections between the
immune system, miRNAs and growth control and thus,
tumorigenesis.Methods
Cell lines and patient samples
Melanoma cell lines A375 (American Type Culture Col-
lection, ATCC), A375-STAT1(F) and A375-STAT1(wt)
[25], FM55P and FM55M1 (European Searchable Tumor
Line Database and Cell Bank, ESTDAB), IGR39 and
IGR37 (Deutsche Sammlung von Mikroorganismen und
Zellkulturen, DSMZ), MeWo (Dr. D. Schadendorf,
Essen, Germany) and SK-Mel30 (Dr. M. Böhm, Münster,
Germany) as well as the T cell lines Jurkat and MT4
(Dr. C. Devaux, Luxembourg) were maintained in
RPMI 1640 supplemented with 10% FCS (PAA), 50 μg/ml
penicillin, 100 μg/ml streptomycin and 0.5 mmol/l
L-glutamine. The stably transfected A375 cell clones
A375-STAT1(F) and A375-STAT1(wt) were grown under
selective pressure with 400 μg/ml Geneticin (G418,
Gibco). HaCaT keratinocytes (Dr. N. Fusenig, Heidelberg,
Germany) and HEK293T were grown in DMEM supple-
mented with 10% FCS, 50 μg/ml penicillin, 100 μg/ml
streptomycin and 2.5% HEPES. NHEM-M2 (normal epi-
dermal human melanocytes, PromoCell) were cultured in
melanocyte growth medium M2 (PromoCell) and har-
vested after reaching ~50% confluence in a 10 cm2 cell
culture dish. All cells were maintained in a humidified at-
mosphere with 5% CO2 and were routinely tested to be
mycoplasma-negative by PCR. Reagents and media were
purchased from Lonza unless specified otherwise.
Ethical approval for use of the patient FFPE (formalin-
fixed paraffin-embedded) and healthy control samples
was obtained by the Ethical review board, Freiburg,
Germany (Reference 196/09). Collection, histopatho-
logical analysis, fixation and RNA extraction were per-
formed as described before [54]. In total, RNAs of 5
healthy skin samples, 4 benign nevi, 12 primary and 14
metastatic melanoma samples were analyzed by qRT-
PCR. The primary and metastatic samples were collected
from different parts of the body from a total number
of 5 melanoma patients. Basal miR-expression levels
were calculated as 2-Δct with Δct= (ct (miR-29a/29b) –
ct (RNU5A)) (Figure 5).
IFN-γ stimulation, RNA extraction, and miRNA microarray
analysis
For IFN-γ time course stimulation experiments, 100x103
cells/well were seeded in 6-well plates (Greiner). Cells
were either left untreated or stimulated with 50 ng/ml of
IFN-γ (PeproTech) for the time periods indicated. 5 μM
Jak inhibitor 1 (JI1, Calbiochem) pre-treatment was
included (72h JI1-time point) in the detailed time course
miRNA microarray experiment one hour before IFN-γ-
stimulation. Samples for RNA extraction and protein
lysates were collected altogether at the end of the treat-
ment for further analyses by qRT-PCR and Western
Blotting, respectively. Total RNA was extracted using
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with DNaseI (New England Biolabs) as described before
[54]. Quantity and purity of RNA samples were assessed
using a NanoDrop ND-2000 spectrophotometer. Global
miRNA expression levels were profiled on Affymetrix
GeneCHip miRNA 2.0 Arrays as described before [13].
Relative quantification of primary, precursor and mature
miRNAs and mRNAs
For FFPE samples and cell lines, 250 ng of total RNA
was reversely transcribed using the miScript Reverse
Transcription kit (Qiagen) according to the supplied
protocol. Real-time PCR was carried out on a CFX de-
tection system (Bio-Rad). For quantification of maturemiRNAs, 5 ng RNA input, 2x iQ SYBR Green Supermix
(Bio-Rad) and 10x miRNA-specific primer assay (Qiagen)
were used. To detect mRNAs, miRNA primary clusters
and precursors, 2x iQ SYBR Supermix and 5 pmol gene-
specific primers (for sequences see Additional file 4:
Table S1) were used together with 50 ng (mRNA detec-
tion) or 125 ng (primary/precursor miRNAs) RNA in-
put. PCR conditions for all qRT-PCR reactions were
95°C-3 min; 39x (95°C-15s; 60°C-30s); 95°C-1 min;
60°C-1 min, followed by a melt curve analysis (60°C to
95°C, increment 0.5°C for 20s) to confirm specificity of
the PCR primers. If not stated otherwise, Ct-values for
mRNA and miRNA species were normalized to at least
three housekeeping genes: TBP (TATA binding protein),
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CycloA (cyclophilin A) and β-Actin for mRNAs and
primary/precursor miRNAs; RNU1A, RNU5A (RNA,
U1A/5A small nuclear) and SCARNA17 (small Cajal
body-specific RNA 17) for mature miRNAs. Based on
the geometric mean of the three reference genes, a
normalization factor was calculated for each sample
using geNorm, a VBA applet for Microsoft Excel [55].
The relative amount of each target in each sample was
then corrected by dividing its amount by the corre-
sponding normalization factor. Fold changes were cal-
culated by dividing the normalized relative amount of
treated samples with the normalized relative amount
of the untreated sample that served as a control. Stat-
istical significance was tested with one-way ANOVA,
followed by a Dunnett Post-Hoc test. Except for the
FFPE patient samples, all experiments were performed
at least in biological triplicates. P values of <0.05 (*),
<0.01 (**) and <0.001 (***) were considered significant.Western blot analysis
Cell lysis, SDS-PAGE, ECL detection, stripping and re-
probing was performed as previously described [56,57]
using the following antibodies: Actin (C4, Milipore),
Tubulin, IRF-1, STAT1 and CDK6 (Santa Cruz), P-STAT1
(Cell Signaling), p85α (PI3K) (Upstate) and the corre-
sponding HRP-labeled (ECL detection, Cell Signaling
Technology) or fluorophor-coupled (quantification, Li-cor
Biosciences) secondary antibodies. For quantification of
proteins, signal intensities were assessed with a Li-cor
Odyssey Infrared Imaging System (Li-cor Biosciences)
and analyzed with the provided software. CDK6 and
p85α signals were normalized to the respective Tubulin
loading controls.Real-time proliferation assays
25 x103 cells/well of eight untreated melanoma cell lines
were seeded in 12-well plates and harvested after 96h of
real-time monitoring in the IncuCyte live-cell imaging
system (Essen Bioscience), which photographed cells in
phase contrast every 3h. RNA was extracted and miR-29
species were amplified by qRT-PCR as described before
[54] and above.
miRNA mimic/inhibitor transfection
100 x103 cells/well were seeded in 6-well plates
and transfected after 24h with 50 nM of each miR-29a
and miR-29b mimics or with 150 nM miR-29a inhibi-
tor or corresponding amounts of negative controls
(Qiagen) using the DharmafectDuo transfection reagent
(Dharmacon) according to the supplied protocol; effi-
cient transfection was confirmed by qRT-PCR (Additional
file 3: Figure S3). For miR-29 target gene expression, RNAand protein lysates were collected 24h, 48h and 72h after
transfection and subsequently analyzed by RT-qPCR and
western blot. Proliferation was monitored by the IncuCyte
cell-imaging system as described above.CDK6 siRNA transfection
50x103 cells were transfected with 75nM ON-TARGET
siRNA or siRNA negative control (si-NC) 24h after
seeding in 6-well plates using the HiPerfect transfection
reagent according to the manufacturer’s instructions
(Qiagen). Proliferation was monitored in the IncuCyte
as described above. CDK6 mRNA and protein levels were
assessed after 24h, 48h and 72h to confirm efficient
down-regulation (Additional file 3: Figure S3C,D).Luciferase reporter gene assays
The parts of CDK6 and PI3KR1 (Phosphatidylinositol
3-kinase) 3’UTRs containing miR-29 binding sites,
CDK6 miR-29a single binding sites and the miR-29a
full complementary sequence were cloned into the
pmirGLO Dual Luciferase miRNA target expression
vector (Promega) downstream of the luciferase gene
(see Additional file 4: Table S1 for primer sequences and
oligonucleotides). A375 cells were seeded at a density of
50 x103 cells/well in 24-well plates one day before trans-
fection. Cells were transiently co-transfected with 500 ng
plasmid and 50 nM miR-29a mimic or negative control
for 48h and 72h. Samples were lysed with 1x Passive
Lysis Buffer (Promega) and luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions.
Firefly was divided by Renilla activity and normalized to
the negative control for each construct. Significance was
assessed by one-way ANOVA followed by a Bonferroni
Post-Hoc test with * p<0.05, ** p<0.01 and *** p<0.001.
Additional files
Additional file 1: Figure S1. Schmitt_et_al_2012_Contains a graphical
representation of array results: Top 10 up-regulated miRNAs (as listed in
Figure 1A) after IFN-γ stimulation for the indicated time periods and 72h
JI1.
Additional file 2: Figure S2. Schmitt_et_al_2012_Contains bar
diagrams of qRT-PCR results: MiR-29a/29b up-regulation after IFN-γ-
stimulation and unchanged miR-25 levels in A) HEK293T kidney and B)
Jurkat T cells. C) MiR-29a/29b up-regulation after IFN-α-, IFN-β- and IFN-γ-
stimulation (50 ng/ml) in MT4 T cells.
Additional file 3: Figure S3. Schmitt_et_al_2012_Contains bar
diagrams of qRT-PCR results an western blots: Tracking of miR-29a/29b
mimics in A375 cells (A) and miR-29a suppression after inhibitor
transfection in FM55P cells (B); and knock-down of CDK6 mRNA (C) and
protein levels (D) in both cell lines.
Additional file 4: Table S1. within Schmitt_et_al_2012_Contains primer
sequences. Additional Figure legends: Schmitt_et_al_2012_ Contains
additional Figure legends. Powerpoint documents.
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